Frank S. Lieberman - Concepedia

Author

Frank S. Lieberman

Also Known As

Aldape, Kenneth, Edina Komlodi-Pasztor, F LIEBERMAN, F Lieberman, F. Lieberman, F. S. Lieberman, F.S. Lieberman, Frank Lieberman, Frank S Lieberman, Frank S. Lieberman

339

Publications

12.3K

Citations

H-Index

113

Concepts

All Affiliations

University of Pittsburgh University of Pittsburgh Medical Center Memorial Sloan Kettering Cancer Center The University of Texas MD Anderson Cancer Center Dana-Farber Cancer Institute

About

Frank S. Lieberman is an author at University of Pittsburgh specializing in medicine, neuro-oncology, and glioma.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	28	54	3.3K
2	Health Sciences	14	15	832
3	Engineering	4	4	94
4	Nursing	1	1	10
5	Public Health	1	1	13

Frank S. Lieberman

Publications

11.1K

Citations

H-Index

Page 1

	Year	Citations
Effect of Tumor-Treating Fields Plus Maintenance Temozolomide vs Maintenance Temozolomide Alone on Survival in Patients With Glioblastoma Roger Stupp, Sophie Taillibert, Andrew A. Kanner, JAMA	2017	2.5K
Maintenance Therapy With Tumor-Treating Fields Plus Temozolomide vs Temozolomide Alone for Glioblastoma Roger Stupp, Sophie Taillibert, Andrew A. Kanner, JAMA	2015	1.2K
Effect of Tumor-Treating Fields Plus Maintenance Temozolomide vs Maintenance Temozolomide Alone on Survival in Patients With Glioblastoma Roger Stupp, Sophie Taillibert, Andrew A. Kanner, Zurich Open Repository and Archive (University of Zurich) Neuro-oncologyOncologyMedicineCancer ManagementPathology	2017	641
Induction of CD8<sup>+</sup>T-Cell Responses Against Novel Glioma–Associated Antigen Peptides and Clinical Activity by Vaccinations With α-Type 1 Polarized Dendritic Cells and Polyinosinic-Polycytidylic Acid Stabilized by Lysine and Carboxymethylcellulose in Patients With Recurrent Malignant Glioma Hideho Okada, Paweł Kaliński, Ryo Ueda, Journal of Clinical Oncology	2010	557
Phase I/II Study of Imatinib Mesylate for Recurrent Malignant Gliomas: North American Brain Tumor Consortium Study 99-08 Patrick Y. Wen, W.K. Alfred Yung, Kathleen R. Lamborn, Clinical Cancer Research	2006	426
Progression-free survival: An important end point in evaluating therapy for recurrent high-grade gliomas Kathleen R. Lamborn, W.K. Alfred Yung, Susan M. Chang, Neuro-Oncology Progression-free SurvivalGrade Iii GliomasCancer ManagementPrognosisImportant End Point	2008	416
Differential Sensitivity of Glioma- versus Lung Cancer–Specific EGFR Mutations to EGFR Kinase Inhibitors Igor Vivanco, H. Ian Robins, Daniel Rohle, Cancer Discovery	2012	336
Molecular Study of Malignant Gliomas Treated with Epidermal Growth Factor Receptor Inhibitors: Tissue Analysis from North American Brain Tumor Consortium Trials 01-03 and 00-01 Andrew B. Lassman, Michael R. Rossi, Jeffrey R. Razier, Clinical Cancer Research	2005	246
Phase II Study of Aflibercept in Recurrent Malignant Glioma: A North American Brain Tumor Consortium Study John de Groot, Kathleen R. Lamborn, Susan M. Chang, Journal of Clinical Oncology	2011	220
Therapeutic Impact of Cytoreductive Surgery and Irradiation of Posterior Fossa Ependymoma in the Molecular Era: A Retrospective Multicohort Analysis Vijay Ramaswamy, Thomas Hielscher, Stephen C. Mack, Journal of Clinical Oncology	2016	198

Page 1